These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34399998)

  • 21. Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer.
    Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e64-e72. PubMed ID: 33629479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
    Siva S; Bressel M; Wood ST; Shaw MG; Loi S; Sandhu SK; Tran B; A Azad A; Lewin JH; Cuff KE; Liu HY; Moon D; Goad J; Wong LM; LimJoon M; Mooi J; Chander S; Murphy DG; Lawrentschuk N; Pryor D
    Eur Urol; 2022 Apr; 81(4):364-372. PubMed ID: 34953600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
    Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
    Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
    Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
    Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Loo Gan C; Huang J; Pan E; Xie W; Schmidt AL; Labaki C; Meza L; Bouchard G; Li H; Jackson-Spence F; Sánchez-Ruiz C; Powles T; Kumar SA; Weise N; Hall WA; Rose BS; Beuselinck B; Suarez C; Pal SK; Choueiri TK; Heng DYC; McKay RR
    Eur Urol Oncol; 2023 Apr; 6(2):204-211. PubMed ID: 36328934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
    Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
    Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
    Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma.
    Zengin ZB; Govindarajan A; Salgia N; Sayegh N; Tripathi N; Muddasani R; Chehrazi-Raffle A; Feng M; Mercier BD; Ladbury C; Hao C; Salgia S; Chawla N; Meza L; Malhotra J; Dizman N; Hsu J; Castro DV; Barragan-Carrillo R; Ebrahimi H; Philip EJ; Chang M; Zhang J; Byron S; Lyou Y; Dorff T; Pal SK; Dandapani S
    Eur Urol Oncol; 2023 Aug; 6(4):447-450. PubMed ID: 36609061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.
    Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N
    Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.
    Le UT; Passlick B; Schmid S
    J Thorac Dis; 2023 Mar; 15(3):1133-1141. PubMed ID: 37065601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer.
    Ying X; You G; Shao R
    Transl Cancer Res; 2024 May; 13(5):2408-2418. PubMed ID: 38881915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
    Ingrosso G; Detti B; Fodor A; Caini S; Borghesi S; Triggiani L; Trippa F; Russo D; Bruni A; Francolini G; Lancia A; Marinelli L; Di Muzio N; Livi L; Magrini SM; Maranzano E; Musio D; Aristei C; Valeriani M
    Clin Transl Oncol; 2021 Aug; 23(8):1577-1584. PubMed ID: 33495981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
    Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
    Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma.
    Onal C; Hurmuz P; Guler OC; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
    Clin Transl Oncol; 2022 Aug; 24(8):1533-1541. PubMed ID: 35119653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
    Peng P; Gong J; Zhang Y; Zhou S; Li Y; Han G; Meng R; Chen Y; Yang M; Shen Q; Chu Q; Xia S; Zhang P; Zhang L; Chen Y; Zhang L
    Radiother Oncol; 2023 Jul; 184():109681. PubMed ID: 37105304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
    Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
    Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.